Therefore, it was the aim to further elucidate the modulation of the metastatic capability by the Ephrin-B2–EphB4 pathway in a ligand-dependent and ligand-independent retrograde carotid artery injection melanoma metastasis model and to validate its potential for future therapeutic strategies. This evidence concerns the gene EPHB4 and melanoma.